Truist initiated coverage of Teva (TEVA) with a Buy rating and $25 price target Teva’s dual focus on cultivating its high-margin brands while strengthening generics continues to de-risk the topline and margin profile, says the analyst, who sees management executing well against the company’s “Pivot to Growth” plan. The firm sees potential line of sight to 30% operating margin by 2027, the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue